All In Biotech

Drug Trial Radar · NCT06720987

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Feb 4, 2025

Primary completion

Jun 30, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Kumquat Biosciences Inc.Industry
Sponsor type
Industry
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198? * Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198. * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.

Conditions

  • KRAS G12C Mutation
  • KRAS G12S Mutation
  • Solid Tumor Malignancies
  • CRC (Colorectal Cancer)
  • NSCLC
  • NSCLC (Non-small-cell Lung Cancer)
  • NSCLC Non-small Cell Lung Cancer
  • Lung Cancer (Non-Small Cell)
  • KRAS G12-mutant NSCLC

Interventions

  • KQB365Drug

    Intravenous KQB365

  • CetuximabDrug

    Intravenous cetuximab

  • KQB198Drug

    Oral KQB198

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: From enrollment to the end of treatment
  2. Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: up to 35 months
  3. Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Part 2)Time frame: up to 35 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic, Phoenix

    Phoenix, Arizona · Recruiting

  • Sarah Cannon Cancer Institute at HealthONE

    Denver, Colorado · Recruiting

  • Mayo Clinic, Jacksonville

    Jacksonville, Florida · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic, Rochester

    Rochester, Minnesota · Recruiting

  • Cleveland Clinic, Taussig Cancer Institute

    Cleveland, Ohio · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Sydney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia, LLC

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.